Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer

References

• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
   PubMed Web of Science ®Google Scholar
• Guérin A, Sasane M, Zhang J, et al. Brain metastases in patients with ALK + non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 2015;18:312-22
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-23
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lim H-J, Park JS, et al. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med 2014;108:388-94
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917-29
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829-38
   PubMed Web of Science ®Google Scholar
• Ou SHI, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-22
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Zykadia(tm) [package insert]. Novartis Pharmaceuticals, East Hanover, NJ, USA; 2014
   Google Scholar
• Kim D-W, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016;17:452-63
   PubMed Web of Science ®Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). 2015 ASCO Annual Meeting. Abstr J Clin Oncol 2015;33(suppl):abstr 8059
   Google Scholar
• Genentech. ALECENSA(R) [package insert]. Genentech, South San Francisco, CA, USA; 2015
   Google Scholar
• Camidge DR, Gadgeel S, Ou S-H, et al. MA07.02 Updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2017;12:S378
   Web of Science ®Google Scholar
• Barlesi F, Dingemans A-MCA, Yang JCJ.-H, et al. Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK + non-small-cell lung cancer (NSCLC). Ann Oncol 2016;27(suppl_6):1263P
   Google Scholar
• ARIAD. ALUNBRIG(tm) [package insert]. ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA; 2017
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2. Med Decis Mak 2013;33:607-17
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics 2015;33:537-549
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Swallow E, Kantor E, et al. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Exp Hematol Oncol 2013;2:32
   PubMedGoogle Scholar
• Signorovitch JE, Wu EQ, Betts K, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin 2011;27:1263-71
   PubMed Web of Science ®Google Scholar
• Tan DS-W, Araújo A, Zhang J, et al. Comparative efficacy of ceritinib and crizotinib as initial ALK-targeted therapies in previously treated advanced NSCLC: an adjusted comparison with external controls. J Thorac Oncol 2016;11:1550-7
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 2011;11:139
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in submissions to Nice. Nice Dsu Tech Support Doc 18 2016;(December). Available at: http://nicedsu.org.uk/technical-support-documents/population-adjusted-indirect-comparisons-maic-and-stc [Last accessed 25 August, 2018]
   Google Scholar
• Ou S-HI, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-93
   PubMed Web of Science ®Google Scholar
• Soo RA, Kawaguchi T, Loh M, et al. Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncol 2012;8:451-62
   PubMed Web of Science ®Google Scholar
• Ou S, Salgia R, Clark J, et al. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol 2017;5:S382
   Google Scholar
• Simmons CP, Koinis F, Fallon MT, et al. Prognosis in advanced lung cancer—a prospective study examining key clinicopathological factors. Lung Cancer 2015;88:304-9
   PubMed Web of Science ®Google Scholar
• Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016;34:123-9
   PubMed Web of Science ®Google Scholar
• Gebbia V, Galetta D, De Marinis F. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials. Ann Oncol Off J Eur Soc Med Oncol 2005;16(Suppl 4):iv123-31
   PubMedGoogle Scholar
• Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
   PubMed Web of Science ®Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016;374:54-61
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Lee J, Huang J, et al. Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts). Ann Oncol 2017;28(suppl_2):mdx091.025
   Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Heal 2012;15:940-7
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Final appraisal determination Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. Report. NICE; 2014. Available at: https://www.nice.org.uk/guidance/ta311 [Last accessed 25 August, 2018]
   Google Scholar
• NICE. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia. Report. NICE; 2012. Available at: https://www.nice.org.uk/guidance/ta426 [Last accessed 25 August, 2018]
   Google Scholar
• Huber RM, Kim DW, Ahn MJ, et al. Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK + non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status [abstract]. J Clin Oncol 2018;36(suppl):9061
   Google Scholar
• Costa RB, Costa RLB, Talamantes SM, et al. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget 2018;9:22137-46
   PubMedGoogle Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017;18:874-886
   PubMed Web of Science ®Google Scholar
• Novello S, Mazieres J, Oh I, et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK + non-small-cell lung cancer (NSCLC). Ann Oncol 2017;28(suppl_5):v605-v649
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer v3.2018. Plymouth Meeting, PA, USA: National Comprehensive Cancer Network; 2018. Available online at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 1 August, 2018]
   Google Scholar